quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·57d
PRRelease
Edgewise Therapeutics Inc. logo

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

EWTX· Edgewise Therapeutics Inc.
Health Care
Original source

Companies

  • EWTX
    Edgewise Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Sep 25UpdateGoldman$20.00
  • Jul 30UpdateRaymond James$46.00
  • Jun 30UpdateH.C. Wainwright$42.00
  • Apr 30UpdateGuggenheim$41.00
  • Apr 2UpdateScotiabank$14.00
  • Mar 7UpdateScotiabank$50.00

Related

  • SEC21h
    SEC Form DEFA14A filed by Edgewise Therapeutics Inc.
  • SEC21h
    SEC Form DEF 14A filed by Edgewise Therapeutics Inc.
  • INSIDER20d
    SEC Form 4 filed by Fox Jonathan C
  • INSIDER22d
    SEC Form 4 filed by Donovan Joanne M.
  • PR23d
    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
  • INSIDER23d
    SEC Form 4 filed by Donovan Joanne M.
  • INSIDER24d
    SEC Form 4 filed by Donovan Joanne M.
  • SEC27d
    SEC Form 144 filed by Edgewise Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022